[HTML][HTML] SARS-CoV-2 B. 1.617 emergence and sensitivity to vaccine-elicited antibodies

I Ferreira, R Datir, G Papa, S Kemp, B Meng, P Rakshit… - BioRxiv, 2021 - biorxiv.org
Abstract The B. 1.617 variant emerged in the Indian state of Maharashtra in late 2020 and
has spread throughout India and to at least 40 countries. There have been fears that two key …

[HTML][HTML] Sensitivity of SARS-CoV-2 B. 1.1. 7 to mRNA vaccine-elicited antibodies

DA Collier, A De Marco, IATM Ferreira, B Meng… - Nature, 2021 - nature.com
Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is
compounded in some areas by the higher transmission potential of the B. 1.1. 7 variant …

[HTML][HTML] SARS-CoV-2 B. 1.1. 7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies

DA Collier, A De Marco, IATM Ferreira, B Meng, R Datir… - MedRxiv, 2021 - ncbi.nlm.nih.gov
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission is
uncontrolled in many parts of the world, compounded in some areas by higher transmission …

SARS-CoV-2 B. 1.1. 7 escape from mRNA vaccine-elicited neutralizing antibodies

R Gupta, D Collier, A De Marco, I Ferreira, B Meng… - 2021 - researchsquare.com
SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in some
areas by higher transmission potential of the B1. 1.7 variant now seen in 50 countries. It is …

[HTML][HTML] Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

TA Bates, HC Leier, ZL Lyski, SK McBride… - Nature …, 2021 - nature.com
SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the
rollout of effective vaccines. Therefore, it is essential to understand the levels of protection …

SARS-CoV-2 B. 1.617 mutations L452R and E484Q are not synergistic for antibody evasion

IATM Ferreira, SA Kemp, R Datir, A Saito… - The Journal of …, 2021 - academic.oup.com
Abstract The SARS-CoV-2 B. 1.617 variant emerged in the Indian state of Maharashtra in
late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain …

Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine …

T Tada, BM Dcosta, M Samanovic-Golden, RS Herati… - BioRxiv, 2021 - biorxiv.org
The increasing prevalence of SARS-CoV-2 variants with mutations in the spike protein has
raised concerns that recovered individuals may not be protected from reinfection and that …

[HTML][HTML] Evolving antibody evasion and receptor affinity of the Omicron BA. 2.75 sublineage of SARS-CoV-2

Q Wang, Z Li, Y Guo, IA Mellis, S Iketani, M Liu, J Yu… - Iscience, 2023 - cell.com
Summary SARS-CoV-2 Omicron BA. 2.75 has diversified into multiple subvariants with
additional spike mutations and several are expanding in prevalence, particularly CH. 1.1 …

Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination

MV Stankov, A Cossmann, A Bonifacius… - medRxiv, 2021 - medrxiv.org
Vaccine-induced neutralizing antibodies are key in combating the COVID-19 pandemic.
However, delays of boost immunization due to limited availability of vaccines may leave …

[HTML][HTML] The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

J Zou, X Xie, CR Fontes-Garfias, KA Swanson… - npj Vaccines, 2021 - nature.com
Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2.
However, the virus has since accumulated mutations, among which the spike D614G is …